Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Napabucasin (BBI608) Plus Paclitaxel in Previously Treated Unresectable/Recurrent Gastric Cancer
jRCT2080222370Phase 1
- Sponsor
- Sumitomo Pharma
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of napabucasin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sumitomo Pharma.
02
Drugs
napabucasin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222370.